Single-cell transcriptomic and functional studies identify glial state changes and a role for inflammatory RIPK1 signaling in ALS pathogenesis
- PMID: 40132594
- DOI: 10.1016/j.immuni.2025.02.024
Single-cell transcriptomic and functional studies identify glial state changes and a role for inflammatory RIPK1 signaling in ALS pathogenesis
Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by motor neuron loss. Microglia and astrocyte-driven neuroinflammation is prominent in ALS, but the cell state dynamics and pathways driving disease remain unclear. We performed single-nucleus RNA sequencing of ALS spinal cords and identified altered glial cell states, including increased expression of inflammatory and glial activation markers. Many of these signals converged on the inflammation and cell death regulator receptor-interacting protein kinase 1 (RIPK1) and the necroptotic cell death pathway. In superoxide dismutase 1 (SOD1)G93A mice, blocking RIPK1 kinase activity delayed symptom onset and motor impairment and modulated glial responses. We used human induced pluripotent stem cell (iPSC)-derived motor neuron, astrocyte, and microglia tri-cultures to identify potential biomarkers that are secreted upon RIPK1 activation in vitro and modulated by RIPK1 inhibition in the cerebrospinal fluid (CSF) of people with ALS. These data reveal ALS-enriched glial populations associated with inflammation and suggest a deleterious role for neuroinflammatory signaling in ALS pathogenesis.
Keywords: ALS; RIPK1; astrocytes; microglia; neuroinflammation; single-nucleus RNA-seq.
Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests M.Z., A.B., F.P., M.L., J.H., O.E.T.-Y., Y.R., S.K.R., C.S., C.M., P.K., M.L., D.S., Y.C., J.G., B.Z., D.S.B., G.G., D.O., and T.R.H. were employees of Sanofi and X.T., J.H.-N., and F.H. were employees of Denali at the time this research was conducted and may hold shares and/or stock options in the companies. J.D.B. has research support from Rapa Therapeutics, MT Pharma of America, ProJenX, Novartis, MDA, ALS Finding a Cure, ALS Association, Association for Frontotemporal Dementia, and NINDS; is an unpaid scientific advisor to Everything ALS; has been a consultant to Denali Therapeutics; and was a paid DSMB member for Sanofi.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous